See the DrugPatentWatch profile for cosentyx

According to the information provided, there is no direct answer regarding whether Cosentyx (secukinumab) passes through breast milk. However, the manufacturer of Cosentyx, Novartis, has stated that it is not known whether the drug is excreted in human milk [1]. The U.S. National Library of Medicine's LactMed database also does not have information on the excretion of secukinumab in breast milk [2].

It is important to note that the lack of information does not necessarily mean that Cosentyx is present in breast milk, but it also does not prove its absence. The U.S. Food and Drug Administration (FDA) classifies Cosentyx as a pregnancy category B drug, which means that animal studies have not shown a risk to the fetus, but there are no well-controlled studies in pregnant women [3].

The decision to use Cosentyx while breastfeeding should be made in consultation with a healthcare provider, taking into account the benefits of breastfeeding, the potential risks to the infant, and the importance of the drug to the mother.

In summary, there is no definitive answer regarding whether Cosentyx passes through breast milk. Further research is needed to determine the safety of the drug during breastfeeding.

Sources:

1. Novartis. Cosentyx (secukinumab) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.
2. National Library of Medicine. Secukinumab. LactMed. 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501891/>.
3. U.S. Food and Drug Administration. Cosentyx (secukinumab) injection, for subcutaneous use. 2021. Available from: <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cosentyx-secukinumab-injection-subcutaneous-use>.
4. DrugPatentWatch. Cosentyx (secukinumab) Patent Expiration & Generics. 2021. Available from: <https://www.drugpatentwatch.com/patent/cosentyx-secukinumab/>.